News CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Market Closed - Hong Kong S.E. Other stock markets 04:09:13 2024-04-23 am EDT			5-day change	1st Jan Change
6.05 ^HKD	+0.83%		+3.07%	-16.67%

Apr. 19	China's drugmakers can't sell mRNA shots but haven't quit yet	RE
Apr. 16	CSPC Pharmaceutical Group Limited commences an Equity Buyback Plan for 1,190,321,973 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2023.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

China's drugmakers can't sell mRNA shots but haven't quit yet	Apr. 19	RE
CSPC Pharmaceutical Group Limited commences an Equity Buyback Plan for 1,190,321,973 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2023.	Apr. 16	CI
CSPC Pharma Secures Chinese Nod for Weight Managment Drug Trials	Mar. 26	MT
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration	Mar. 25	CI
CSPC Pharmaceutical’ Blood Sugar Drug Gets Registration Approval from Chinese Regulator	Mar. 22	MT
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval	Mar. 22	CI
CSPC Pharmaceutical's Cancer Drug Gets China Nod for Clinical Trials	Mar. 21	MT
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China	Mar. 20	CI
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024	Mar. 20	CI
CSPC Pharmaceutical's Profit Falls 4% on Lower Revenue, Misses Estimates	Mar. 20	MT
CSPC Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
CSPC Pharma Obtains Clinical Trial Approval in China for Anti-Tumor Drug	Mar. 19	MT
CSPC Pharmaceutical Group Limited Announces Highly Selective MAT2A Inhibitor Obtains Clinical Trial Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China	Mar. 18	CI
Nomura Adjusts CSPC Pharmaceutical Group’s Price Target to HK$9.41 From HK$8.98, Keeps at Buy	Mar. 14	MT
CSPC Pharmaceutical Obtains New Indication Nod for Mingfule Injection	Feb. 05	MT
CSPC Baike's 2023 Profit Reaches 859 Million Yuan	Jan. 25	MT
U.S. Regulator Allows CSPC Pharmaceutical to Conduct Clinical Trials for Anti-Tumor Drug	Jan. 15	MT
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration	Jan. 15	CI
Values, Inflation Outlook Lift Asian Stock Markets	Jan. 11	MT
CSPC Submits New Drug Application for Pancreatic Cancer Injectable to US FDA	Dec. 18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Summary

Filters